CLU and Alzheimer disease: To date, clusterin is likely to be the most promising potential biomarker of AD-related phenotypes that we have identified in our studies, as supported by an association on the proteomic level with both clinical and neuroimaging measures of AD pathology, on the genetic level with AD risk and on a mechanistic level with amyloid function and processing.